Navigation Links
Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017

Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources

WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just under $250 million in 2007 to more than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin (currently marketed in Japan as Calsed by Nippon Kayaku) to treat the indication.

The new Pharmacor report entitled Small-Cell Lung Cancer finds that the launches, beginning in 2012, of Avastin as a first-line add-on to standard chemotherapy and amrubicin as a second-line therapy will drive robust 22 percent annual growth from 2012 to 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although market growth will be robust from 2012 to 2017, drug development in recent years in small-cell lung cancer has, overall, been very disappointing. Recent clinical trials have largely eliminated Pfizer's Camptosar/Campto (Daiichi Sankyo's Topotecin), Eli Lilly's Alimta, and GlaxoSmithKline/Nippon Kayaku's Hycamtin from potential first-line status in the indication. Furthermore, despite the impressive sales that Avastin and amrubicin will add to the market, these therapies will have only niche roles in small-cell lung cancer treatment.

"Avastin and amrubicin will each garner only a limited share of the total small-cell lung cancer patient population," said Decision Resources Analyst Janie Mackay, Ph.D. "However, their high price points in an increasingly generic market, mean that those patient shares will translate into substantial market shares."

Despite the disappointing drug development environment, the recent designation of small-cell lung cancer as an orphan disease -- owing to reduced growth rates of the indication -- may help drive future drug development. In the United States, a drug approved to treat an orphan disease receives seven years' market exclusivity and in Europe orphan drugs generally receive 10 years' marketing exclusivity.

"If a drug developer were to produce a novel efficacious agent for small-cell lung cancer, they would benefit from the financial advantages that orphan-drug designation offers in the world's major pharmaceutical markets," Dr. Mackay said.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

          All company, brand, or product names contained in this
        document may be trademarks or registered trademarks of their
                       respective holders.

    For more information, contact:

    Decision Resources            Decision Resources, Inc.
    Christopher Comfort           Elizabeth Marshall
    781-296-2597                  781-296-2563

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: